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Abstract
This clinical study was based on experimental results obtained
in nude mice grafted with human colon carcinoma, showing that
injected 131I-labeled F(ab)2 and Fab fragments from high affinity
anti-carcinoembryonic antigen (CEA) monoclonal antibodies
(MAb) gave markedly higher ratios of tumor to normal tissue
localization than intact MAb. 31 patients with known colorectal
carcinoma, including 10 primary tumors, 13 local tumor recur-
rences, and 21 metastatic involvements, were injected with '13I-
labeled F(ab')2 (a = 14) or Fab (a = 17) fragments from MAb
anti-CEA. The patients were examined by emission-computerized
tomography (ECT) at 6, 24, and sometimes 48 h after injection
using a rotating dual head scintillation camera. All 23 primary
tumors and local recurrences except one were clearly visualized
on at least two sections of different tomographic planes. Inter-
estingly, nine of these patients had almost normal circulating
CEA levels, and three of the visualized tumors weighed only 3-
5 g. Among 19 known metastatic tumor involvements, 14 were
correctly localized by ECT. Two additional liver and several bone
metastases were discovered by immunoscintiraphy. Altogether,
86% of the tumor sites were detected, 82% with F(ab')2 and 89%
with Fab fragments. The contrast of the tumor images obtained
with Fab fragments suggests that this improved method of im-
munoscintigraphy has the potential to detect early tumor recur-
rences and thus to increase the survival of patients. The results
of this retrospective study, however, should be confirmed in a
prospective study before this method can be recommended for
the routine diagnosis of cancer.
Introduction
After experimental work in nude mice and in hamsters hetero-
grafted with human colon carcinoma (1, 2), large series ofpatients
have been injected with '31I-labeled, purified polyclonal anti-
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bodies against carcinoembryonic antigen (CEA)' (3) in order to
detect tumors by planar scintigraphy (4-10) (Delaloye et al.,
unpublished results). In these studies some striking cases oftumor
detection were obtained with what should be called the first gen-
eration ofimmunoscintigraphy (polyclonal antibodies and planar
scintigraphy). Major differences emerged, however, in the in-
terpretation ofthe clinical results obtained. Goldenberg's group
claimed that the results obtained with the first generation of
immunoscintigraphy were already clinically useful (4, 9, 10),
whereas our group, despite the use of goat anti-CEA antibodies
giving specific tumor to normal tissue ratios in 58 colorectal
carcinoma patients, concluded that the technology of immu-
noscintigraphy should be improved before it could be usefully
applied in the diagnosis of carcinoma (5, 6).
In 1981, the first monoclonal anti-CEA antibody (MAb) 23,
which had an affinity of 5.7 X 108 M' (11), was studied in a
series of 31 colorectal carcinoma patients tested by planar scin-
tigraphy (12). The results were slightly improved as compared
with polyclonal antibodies, in the sense of less nonspecific ac-
cumulation of the tracer in the reticuloendothelial system, but
they were not yet considered satisfactory for clinical application.
The same MAb 23 was tested in an additional series of 16 patients
with colorectal carcinoma and medullary thyroid carcinomas,
using for the first time emission-computerized tomography
(ECT) for detection of labeled antibodies (12, 13). With this
second generation of immunoscintigraphy, the results were en-
couraging in terms of sensitivity (16-17 tumors detected) but
the signal-to-noise ratio was not very high, in part due to the
poor detection efficiency of '" I by the camera and in part to the
relatively low affinity ofMAb 23.
As a further way of improving this technique we produced
an additional series of 26 new anti-CEA MAb, which were se-
lected first in vitro on the basis of high affinity for CEA and
absence of crossreactivity with granulocyte glycoproteins (14,
15), and second, in vivo in the nude mouse model for good lo-
calization in human colon carcinoma heterograft (14). The MAb
with the highest affinity for CEA (5.8 X 109 M-') and no cross-
reactivity with granulocytes was MAb 35. In addition, F(ab')2
and Fab fragments from MAb 35 were shown to give 3 and 12
times, respectively, higher tumor to normal tissue ratios as com-
pared with intact MAb 35, in the nude mouse model (16). Thus,
in this experimental model, Fab fragments, which have a single
1. Abbreviations used in this paper: CEA, carcinoembryonic antigen; CT
scan, x-ray computerized tomography; ECT, emission-computerized to-
mography (also called SPECT, single photon emission-computerized to-
mography); MAb, monoclonal antibodies.
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binding site and about one-third the size of an intact antibody,
gave the most clear-cut tumor localization.
Here we present the results obtained in a series of 31 colo-
rectal carcinoma patients injected with '23I-labeled F(ab')2 or
Fab fragments from MAb 35 and tested by ECT, using a dual
head rotating camera. This third generation of immunoscintig-
raphy has four advantages over the first generation: (a) the use
of a highly selected MAb, with high affinity for CEA and no
crossreaction with granulocytes (a crossreaction which has been
reported to provoke major problems with many anti-CEA MAb)
(17); (b) the use of MAb fragments, which have been shown to
be more rapidly eliminated from the circulation and to penetrate
better into tumors (16, 18); (c) the use of ECT, eliminating the
necessity of subtraction techniques which are susceptible to the
formation of artifacts ( 19); (d) the use of 1231, which appears to
be one ofthe most convenient isotopes for imaging with gamma
cameras (20, 21).
The purpose ofthe retrospective clinical study reported here
is to evaluate the improvement in the detection ofknown colon
carcinoma sites by this new generation of immunoscintigraphy.
A prospective clinical trial is ongoing to compare this method
with other modern methods of tumor detection.
Methods
An unselected series of 31 patients (21 males aged 35-82 [mean 63] yr,
and 10 females aged 35-80 [mean 58] yr) with known colorectal carci-
noma, diagnosed by contrast medium enema, rectosigmoidoscopy, co-
lonoscopy, x-ray computerized tomography (CT scan), ultrasound, bone
scan and/or radiography, was studied. Tables I-III show the clinical fea-
tures for 10 patients with primary tumors (all of them were operated
within 20 d after the present study), 13 patients having local recurrences
with or without metastases (time between first operation and present
study ranged from 1 to 28 mo; mean, 13 mo) and 8 with only distant
metastases (time between first operation and study ranged from 5 to 50
mo; mean, 28 mo). The metastases were localized in the liver (n = 14),
in the bone (n = 3), in the lung (n = 2), or in the peritoneum (n= 2). In
four of these patients, metastatic involvement of the liver (n = 2), or
bone (n = 2) was first detected by immunoscintigraphy and confirmed
thereafter. Dukes' stage was determined at the first operation according
to the original Dukes' classification with the addition of Dukes' D for
distant metastases.
The thyroid was blocked by oral administration of Lugol's 5% Iodine
solution (50 mg/d) for 2 d before and 3 d after injection. The thyroidal
uptake was not more than 1% of the injected dose of 123l as determined
at 6 and 24 h.
To prevent allergic reactions, 16 and 1 h before injection the patients
received an antihistaminic drug (Clemastine, 2 mg); in addition, 100 mg
ofprednisolone was injected intravenously 1 h before the administration
of the antibody. No intracutaneous testing was performed. None of the
31 patients injected showed any adverse effect or any sign of discomfort
during or after the injection of radiolabeled MAb.
One patient received the F(ab')2 fragments of anti-CEA MAb 202,
13 patients F(ab')2, and 17 patients Fab fragments of anti-CEA MAb
35. The fragments were prepared by pepsin or papain digestion, respec-
tively, as previously described (16). 1.5 mg of F(ab')2 or I mg of Fab
fragments labeled with 2.3-8.0 (mean, 3.95 SD± 1.04) mCi of 1231 were
given in a 1-h i.v. perfusion. 1231 was produced from the 1271I (p, 5n) 123Xe
reaction and generously provided by the Swiss Federal Institute for Re-
actor Research, Wurenlingen, Switzerland. The antibody fragments were
simultaneously labeled with 0.07 mCi of 1251I to allow in vitro activity
measurements of surgical specimens, as well as of late blood and urine
samples. The labeling was performed at 4°C by the Iodogen method
(Pierce Chemicals Co., Rockford, IL). Labeled antibody was separated
from free iodine by chromatography on a Sephadex G-25 (Pharmacia
Fine Chemicals, Uppsala, Sweden) column equilibrated in pyrogen-free
0.15 M saline and sterilized by filtration through a 0.22-'sm Millipore
filter (Millipore/Continental Water Systems, Bedford, MA) and tested
for sterility and absence of pyrogenicity (in rabbits). All antibody prep-
arations were tested for immunoreactivity by incubation with CEA cou-
pled to cyanogen bromide (CNBr)-activated Sepharose (Pharmacia Fine
Chemicals), as previously described (16). The percentage of binding of
the labeled MAb fragments to insolubilized CEA ranged from 52 to 75%
(mean 59%).
Anterior and posterior whole body scans were performed simulta-
neously at 1, 6, 24, and 48 h after injection by the means of a rotating
dual head scintillation camera, ROTA camera (Siemens, Inc., Erlangen,
West Germany) equipped with a whole body attachment and linked
with an array processor (Computer Design and Applications Inc., Wal-
tham, MA) and a computer (PDP 11/44, Digital Equipment Corporation,
Maynard, MA). ECT studies of the lower and upper abdomen were
performed at 6 and 24 h in all patients and also at 48 h in 11 patients.
Additional regions were studied by ECT when other metastatic lesions
were suspected.
For all tomographic reconstructions, 30 views per camera head were
stored with an angular increment of 60, using low energy all-purpose
Table I. Clinical Features and Immunoscintigraphic Results from Patients with Primary Tumors
Scintigraphic resultst
Primary Liver
Patient no./age/sex Primary tumor Dukes' stage Tumor weight Serum CEA MAb fragments* Injected activity tumor metastases
g sg/Iliter mCi 123-
1/80/M Right colon C 27 125 F(ab')2 3.4 +
2/60/M Rectum B 40 4 F(ab')2 3.2 +
3/60/M Sigmoid C 15 4 F(ab)2 4.3 +
4/75/M Right colon C 26 2 F(ab')2 3.4 +
15/76/M Right colon C 33 51 Fab 4.8 + +
16/62/F Sigmoid B 18 3 Fab 2.3 +
17/80/F Left colon B 3 2 Fab 4.2 +
18/56/M Rectum A 4.5 25 Fab 5.1 +
19/70/F Sigmoid D 50 1,370 Fab 4.2 + +
20/55/F Sigmoid C 5 2 Fab 8.0 + +
* All fragments were from monoclonal anti-CEA antibody no. 35 except for patient 1, who received F(ab')2 from MAb 202. t The + sign indi-
cates primary or metastatic tumor sites that were visualized on at least two sections of different tomographic planes.
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Table II. Clinical Features and Immunoscintigraphic Resultsfrom Patients with Local Recurrences
Scintigraphic results
Distant metastases
Local
Patient no./age/sex Primary tumor Dukes' stage Serum CEA MAb fragments Injected activity recurrences Liver Other
Sigmoid
Rectum
Rectum
Sigmoid
Rectum
Caecum
Sigmoid
C
C
B
C
A
C
D
pg/liter
240
86
1,200
13
11
7
7
Right colon B
Sigmoid
Rectum
Rectosigmoid
Right colon
Sigmoid
F(ab%2
F(ab)2
F(ab)2
Fab
Fab
Fab
Fab
140 Fab
B
B
B
B
C
48
415
800
3
2
Fab
Fab
Fab
Fab
Fab
* The + sign indicates tumor sites that were visualized on at least two sections of different tomographic planes. The - sign indicates tumor sites
that were not clearly visualized by immunoscintigraphy.
collimators. At 6 h post injection, an average of 70,000 counts per view
were collected in about 30-s exposures; at 24 h, 50,000 counts in 60 s;
and at 48 h, some 30,000 counts in 120 s. For all regions examined,
transverse, sagittal, and coronal sections were reconstructed. A tumor
site was considered as positive only when an uptake of radioactivity
corresponding to the suspected tumor location was clearly detected on
at least two sections from different tomographic planes and at two different
time intervals. Following the last '"I-ECT, 4 mCi ofTc-99m sulfur colloid
was injected and another ECT ofthe liver was performed, with the patient
remaining in the same position. No substraction techniques were used.
The data were filtered during reconstruction. Smoothing and adjustment
oflower and upper thresholds were performed when necessary for better
visualization oftumors (voxels out of thresholds were set zero = black).
The camera was checked daily for center alignment, offset, uniformity,
and sensitivity of both heads. The slice thickness of the reconstructed
sections was 12 mm.
The serum CEA levels were measured by a solid-phase enzyme im-
munoassay using three different monoclonal anti-CEA antibodies (22).
The normal level of serum CEA using this assay ranged from 0 to 5 Asg/
liter.
Results
Tumor status and immunoscintigraphy data for all patients are
summarized in Tables I-III. Table I shows that all primary tu-
mors have been visualized by this technique with both types of
fragments and regardless of the level of circulating CEA.
Fig. 1 illustrates the detection of a carcinoma of the caecum
on a coronal (i.e., frontal) ECT section of the lower abdomen
and pelvis from patient 1. The F(ab')2 fragments from MAb
anti-CEA 202 injected in this patient were avidly taken up by
the tumor, as confirmed by direct measurement of the radio-
activity in resected tumor and adjacent tissues (Fig. 2 A). MAb
Table III. Clinical Features and Immunoscintigraphic Resultsfrom Patients with only Metastatic Disease
Scintigraphic results*
Metastases to
Patient no./age/sex Primary tumor Dukes' stage Serum CEA MAb fiagments Injected activity Liver Others
pg/liter mCi 123-
8/59/M Rectum C 1,150 F(ab')2 4.4 +
9/65/M Sigmoid C 2,500 F(ab%2 3.5 - - lung
10/68/M Rectosigmoid C 52 F(abI)2 4.4 +
11/47/F Sigmoid C 70 F(abr)2 4.7 + bone
12/76/F Right colon B 72 F(ab)2 3.2 +
13/70/F Rectum C 2,100 F(ab')2 3 + + bone
14/59/M Left colon D 34 F(ab%2 3.7
31/46/M Caecum C 17 Fab 4.7 + + lung
* See Table II.
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5/61 /M
6/44/F
7/80/M
21/64/M
22/66/M
23/61/F
24/76/M
25/35/F
26/35/F
27/53/M
28/40/M
29/82/M
30/57/M
mCi 123-
3.6
2.9
3.3
3.7
4.0
8.0
4.3
3.8
4.1
4.5
2.5
4.9
4.2
+
+
+
+
+
+
+
+
+
+
+
+
+
- peritoneum
{+ bone
- peritoneum
+
+
Figure 1. Uptake of MAb 202 F(ab'`) fragments in tumor but also in
bone marrow. The coronal section (C) of patient I with a carcinoma
of the caecum obtained 24 h after injection shows avid uptake of the
antibody by the tumor (T) as confirmed by in vitro counting of the
surgical specimen (Fig. 2 A), but also visualization of bone marrow
(BM) which seems to be related to the crossreaction ofMAb 202 with
granulocyte glycoproteins (15). The colors red, yellow, green, and blue
correspond to the degree of concentration of radioactivity: red is high
and blue is low.
202, however, was injected in only one patient because it was
found to bind to granulocytes (15) and to be taken up by the
normal bone marrow, as demonstrated in patient 1 (Fig. 1).
Fragments of MAb 35 did not bind to granulocytes (15). They
were injected in the next 30 patients and did not show uptake
of radioactivity in the normal bone marrow.
Fig. 3 shows transverse sections taken at the same level of
the middle abdomen at different times after injection of Fab
fragments from MAb 35 in patient 15. The sections cut across
a right colon tumor and the large abdominal vessels (aorta and
inferior vena cava). At 6 h after injection vascular activity ex-
ceeded tumor activity, which was, however, already detectable.
The tumor to blood circulation activity ratio increased with time,
being near one at 24 h and definitely higher at 48 h. In our
experience all but one primary tumor has been clearly distin-
guished on the 6-h scans, but the most reliable images have been
obtained after 24 h. Images obtained more than 24 h after in-
jection often had artifacts created by patient movement in the
case oflong data collection times or by statistical uncertainty in
Figure 4. Detectability of small tumors. The tumor (arrow) presented
on this figure weighed only 3 g and was located just distal to the
splenic angle (patient 17). On the transverse section shown, the tumor
is anterior to the left kidney (k). By 6 h after injection, tumor activity
exceeded vascular activity (V). L, left.
the case of shorter ones. The tumor of the patient presented in
Fig. 3 was rather large, weighing 33 g and having a maximum
diameter of 6 cm. Detectability of primary tumors by ECT,
however, does not appear to be related to tumor size.
The smallest tumor in this series was detected in patient 17
after injection of Fab fiagments from MAb 35. It weighed 3 g
and was a primary tumor of the descending colon situated just
distal to the splenic angle. In spite of its small size, it was easily
distinguished on the 6-h transverse section as a unique hot spot
anterior to the left kidney (Fig. 4). Kidneys take up radioactivity
during 24 h after injection and can be used as landmarks.
It is sometimes difficult to distinguish tumor from bladder
activity when the tumors are located in the lower pelvis, as in
patient 18 who had a carcinomatous polyp ofthe recto-sigmoid
weighing only 4.5 g, which was detected with Fab fragments of
MAb 35. On the transverse section, tumor activity could not be
separated from bladder activity, whereas on the 24-h sagittal
section (Fig. 5) the tumor appeared as a well-delineated area of
ectopic activity behind the bladder. The uptake of radioactivity
by this tumor was confirmed by direct counting of the tissues
after surgical resection (Fig. 2 C).
The detection of a 5-g sigmoid tumor in patient 20 is dem-
onstrated in Fig. 6. In a coronal section of the lower abdomen
obtained 24 h after injection of Fab fragments from MAb 35,
the tumor is well defined on the upper left of the pelvis and
Figure 3. Change of tumor-
to-blood activity ratio with
time. The transverse sec-
tions of the lower abdomen
of patient 15 across a right
colon carcinoma (closed ar-
row) and large vessels (open
arrow) at different time in-
tervals after injection of la-
beled Fab fragments from
MAb 35 show a progressive
increase of tumor-to-blood
ratio. Tumor activity is
lower than blood at 6 h; it
equals it at 24 h; and it ex-
ceeds it at 48 h. L, left.
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Figure 2. Demonstration of the tumor localization ofMAb anti-CEA
fragments by direct measurement of radioactivity in tumor and adja-
cent normal tissues. The results were obtained on surgically resected
tissues from four different patients with colorectal carcinoma injected
with (A) F(ab')2 fragments from MAb 202 (patient 1), (B) F(ab')2 frag-
ments from MAb 35 (patient 4), and (C and D) Fab fragments from
distinct from the radioactivity in the urinary bladder. This tumor
was resected 5 d after injection and the radioactivity in tumor
and adjacent normal tissues was compared (Fig. 2 D).
Table II summarizes the results obtained in patients with
local tumor recurrences. All but one local recurrence could be
visualized by this technique, even in patients with very low or
normal CEA levels. In a single patient (patient 25), the recurrent
tumor at the ileo-colic anastomosis after right colectomy could
not be visualized, whereas Fab fragments were taken up by mul-
tiple bone metastases that had not been suspected before and
were only thereafter confirmed by a conventional bone scan
MAb 35 (patients 18 and 20). The concentration of radioactivity per
gram of tissue is indicated by the vertical bars for tumor, dissected
normal mucosa (N. Mucosa), remaining bowel wall (N. Serosa), nor-
mal fat (N. Fat), and whole blood taken preoperatively. The numbers
in the middle of the oblique lines indicate the tumor-to-normal tissue
ratios.
(Tc-99m dicarboxy-propane-diphosphonate). Fig. 7 shows on
the left panel a sagittal section through the thorax and upper
lumbar spine and on the right panel a coronal section of the
pelvis. Both sections showed multiple hot spots corresponding
to uptake of the labeled antibody.
Altogether, 21 distant tumor involvements (several tumor
sites in one organ or tissue were counted as one) were present
and 16 were correctly localized by ECT (Tables I-IV). There
were only two patients with lung metastases in this series. One
(patient 31 ) showed two distinct sites of uptake of radioactivity
which indicated the presence of two metastatic lesions corre-
Carcinoma Detection by '23I-labeled Monoclonal Antibody Fragments 305
0
'U
0
0
as
I-
5
'U
C.'
z0
c.
U-
B1 8 -
1 6 _
1 4 -
1 2-
1 0 -
8
6
4 -
2-
0~
1 5 -
I.- a
4c 0
L. 0
z -Jm
C
Fab MAb 35
Day 2
2.9 7.5 23.8 2.8
Saab~E
M
0
I-
0
as
0
I-.
M
Ix
a.
I0
2
IL
C)
1 2-
9 -
6-
3:
0
Figure 5. Interference of tumor and bladder activity. Small tumors
near the bladder may not be easily differentiated from urinary activity.
The sagittal section is often the most useful one, as shown here for pa-
tient 18, who presented a 4.5-g carcinomatous polyp of the rectum. 6
h after injection, tumor activity (arrow) is clearly distinct from urinary
activity in the bladder (b), which is located anteriorly. 2 d after injec-
tion, the patient was operated on and specific tumor-to-normal tissues
ratios were observed by direct counting of the radioactivity in tissues
(Fig. 2 C).
sponding exactly with the radiological findings. No uptake of
radioactivity could be demonstrated in two small lung lesions
ofthe other patient (patient 9), who had in addition a large liver
metastasis which also undetected by ECT and a very high serum
CEA level (2,500 ag/liter).
Two regional tumor metastases in the peritoneum were not
detected. One was situated in the lower abdomen of patient 25,
who had in addition multiple bone metastases which took up
Fab fragments and the already mentioned single undetected local
recurrence from this series. One may assume that the accu-
mulation of labeled fragments in the bone metastases prevented
their localization in the local and regional tumor recurrence. In
the other patient with peritoneal involvement (patient 24), the
sigmoid local recurrence was correctly identified, whereas the
peritoneal carcinomatosis remained undetected by immuno-
scintigraphy.
Figure 6. Visualization of a 5-g sigmoid tumor on a coronal section of
the pelvis obtained 24 h after injection in patient 20. Tumor (arrow)
and bladder (b) are well-defined. The relatively high tumor uptake of
Fab fragments was confirmed by direct counting of the resected tumor
and adjacent normal tissues (Fig. 2 D). L, left.
Two patients (patients 15 and 20) with primary tumors had
normal liver CT scan or ultrasound examinations, whereas im-
munoscintigraphy showed antibody uptake in an area of the
liver which proved to be photon deficient on the Tc-99m sulfur
colloid ECT. In both cases, the liver metastases were confirmed
at surgery. Among 12 patients with known liver metastases (as
detected by ultrasound and/or CT scan), 10 had lesions that
took up antibody fragments. Liver involvement was undetected
in two patients, one with liver cirrhosis (patient 9) and the other
with a metastasis located at the site of resection after repeated
partial hepatectomy (patient 14).
ECT studies from two patients with liver metastases will be
presented in further detail. The first patient (patient 12) had a
large metastasis in the posterior part ofthe right lobe of the liver
easily detected by ultrasound. This case is presented (Fig. 8)
because it demonstrates the slow and progressive penetration of
the F(ab')2 fragments within the tumor mass as well as the mor-
phological accuracy of the ECT images.
Patient 15 was not known to have liver metastasis before
immunoscintigraphy. Fig. 9 shows the corresponding transverse
Figure 7. Uptake of MAb fragments in bone metas-
tases. On the sagittal (S) section (left) through the dor-
sal and upper lumbar spine and the sternum as well as
on the coronal (C) section (right) of the pelvis, numer-
ous hot spots are suggestive of multiple bone metas-
tases which were unsuspected at the moment of im-
munoscintigraphy and only subsequently confirmed
by a Tc-99m diphosphonate bone scan. A single dorsal
vertebra (arrow) was considered as free of tumor by
both examinations.
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Figure 8. Progressive penetration of F(ab')2 fragments into a large liver
metastases. Transverse sections across the liver of patient 12 taken at
intervals of 6, 24, and 48 h after injection of the antibody fragment
(upper left and right, and lower left panels). A corresponding ECT sec-
tion obtained after injection of Tc-99m sulfur colloid is shown on the
lower right panel: the tumor appears as a large photon-deficient area
in the posterior part of the right liver lobe on the sulfur colloid ECT
(arrow). On the 6-h immunotomoscintigraphy a circular area of anti-
body uptake with a large central defect is shown, which gradually fills
up, as demonstrated on the 24-h and especially on the 48-h ECT. At
this moment the tumor mass is almost entirely filled with radioactivity
except for a small, probably necrotic central region; whereas most of
the antibody has cleared from normal liver parenchyma. L, left.
Figure 9. Detection of previously unknown liver metastases. The cor- ton-deficient area of the sulfur colloid ECT and corresponds to liver
responding transverse sections of Tc-99m sulfur colloid ECT (left) and metastases, which were confirmed by surgery. The antibody uptake by
immunotomoscintigraphy (right) of the liver obtained from patient 15 normal liver parenchyma is already very low at 24 h after injection of
show that the area of antibody uptake has the same shape as the pho- Fab fragments from MAb 35. L, left.
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sections of the liver after injection ofTc-99m sulfur colloid (left
panel) and after injection of 123I-labeled Fab fragment from MAb
35. The shape of the area of antibody uptake fits well into the
photon-deficient area of the sulfur colloid ECT. The suspected
tumor was confirmed at surgery but could not be resected. In
the other case in which a liver metastasis was discovered by
immunoscintigraphy (patient 20), the liver metastasis was sur-
gically resected. Both of these cases were investigated with Fab
fragments, which showed relatively less accumulation in normal
liver parenchyma on early images than did F(ab')2 fragments.
Our overall results are summarized in Table IV. 38 of 44
organs with tumor involvement were correctly identified. The
detection rate proved to be somewhat higher with Fab (89%)
than with F(ab')2 fragments (82%).
Discussion
The concept of using radiolabeled antibodies to detect hidden
tumor cells (23) has been revitalized by the development of the
MAb technology. For the last 7 yr, however, several thousands
of patients have received injections of radiolabeled polyclonal
or monoclonal antibodies directed against various tumor mark-
ers, with relatively modest clinical results in terms of precision
of tumor imaging (4-10, 24-26). We were among the first to
make a critical evaluation of the results obtained with polyclonal
and monoclonal anti-CEA antibodies labeled with '"'I (5, 12).
We considered that the tumor detection obtained by this method,
particularly after computerized subtraction ofblood pool radio-
activity, was not precise and reliable enough to influence clinical
decisions.
In contrast, the tumor images reported here, obtained by
using ECT and the smallest fragment (Fab) of highly selected
anti-CEA MAb, labeled with 123I represent a marked improve-
ment over previously published results. The high resolution of
the tomographic tumor images strongly suggests that this im-
proved method of immunoscintigraphy has the potential to
Table IV. Visualization of Colorectal Carcinoma with
'23I1-labeled Anti-CEA MAb Fragments and ECT
F(ab)2
Both
fragments Positive/Total Fab
Primary tumors 10/10* 4/4 6/6
Local recurrences 12/13 3/3 9/10
Metastases
Liver 12/14 5/7 7/7
Lung 1/2 0/1 1/1
Bone 3/3 2/2 1/1
Peritoneum 0/2 0/2
Total 38/44 (86%) 14/17 (82%) 24/27 (89%)
* Number of tumor sites visualized in at least two sections from differ-
ent tomographic planes per number of tumors confirmed by conven-
tional methods or by surgery. When several tumor sites were found in
the same organ, or tissue or anatomical region (liver, lung, bone, or
peritoneum) they were counted as one.
compete with the most modern methods of tumor detection. A
controlled prospective clinical trial, however, including system-
atic comparison with results from CT scan, ultrasonography,
and possibly nuclear magnetic resonance results, is still necessary
to confirm this point. If immunoscintigraphy, improved by ECT,
can reach the same sensitivity as the CT scan and nuclear mag-
netic resonance imaging, the immunological method will still
have the advantage that the antibodies detect a tumor marker
within a lesion, whereas the other methods only detect a mor-
phological alteration.
In order to obtain the necessary improvement of colon car-
cinoma detection by immunoscintigraphy, three factors appeared
to be of particular importance: (a) the selection of the most
favorable target tumor marker and the best MAb directed against
this antigen, (b) the choice between intact antibodies and their
F(ab')2 or Fab fragments, and (c) selection ofthe most convenient
isotope. These three factors will be discussed in sequence.
Despite the theoretical disadvantage of CEA, as an antigen
released into the circulation, we chose this marker because our
previous clinical experience showed that we could obtain rela-
tively good ratios oftumor to normal tissue localization despite
the presence of elevated circulating CEA levels (5, 6, 12, 13).
Two other markers associated with colon carcinoma have been
identified by MAb 17-lA (27) and MAb NS 19-9 (28). The an-
tigen recognized by MAb 17-1A is not shed into the circulation,
whereas the antigen recognized by MAb NS 19-9 is released into
the blood. Our experience, based on 53 colon carcinoma patients
injected with '31I-labeled MAb 17-lA (29), was that the tumor
to normal tissues ratios and the immunoscintigraphy results were
not superior to those obtained with our 13'I-labeled anti-CEA
MAb (12, 13). More recently, however, Moldofsky et al. (30)
reported encouraging clinical results with 13'I-labeled F(ab')2
fragments from MAb 17-1 A. Chatal et al. (31) injected 131I-la-
beled MAb 19-9 or its F(ab')2 fragments and detected 66% of
29 colorectal carcinoma sites by planar scintigraphy. This might
be because not all colon carcinomas express the 19-9 antigen.
A large series of colorectal carcinoma patients have been tested
by immunoscintigraphy using a MAb directed against human
osteosarcoma cells (24). It appears unlikely, however, that a single
MAb which has been found to react with very different types of
tumors could be more specific than highly selected MAb against
a well-defined marker such as CEA. Another MAb of potential
interest for immunoscintigraphy ofcolon carcinoma is the MAb
B72.3 anti-breast carcinoma. It localized well in colon carcinoma
grafted into nude mice (32), but only preliminary clinical results
have been reported (33).
The anti-CEA MAb 35 used in this study was selected out
of more than 30 anti-CEA MAb by the criteria of high affinity
(5.8 X 109 M-') for CEA and absence of crossreactivity with
granulocyte glycoproteins (14-16).
The selection of the antibody fragments was based on our
experimental results obtained in nude mice grafted with human
colon carcinoma. '3'I-labeled F(ab')2 or Fab from MAb 35 gave
3.5 and 11.7 times higher tumor to normal tissue ratios, re-
spectively, than intact MAb 35 (16). Furthermore, when we
started to inject the Fab fragments into patients [after having
used F(ab')2 in the first 13 patients of this study], we noticed an
improvement in the quality of the tumor images (earlier tumor
uptake, less background radioactivity in spleen and liver); thus
we injected all the following patients with Fab from MAb 35.
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In fact, 6 out of 8 of the figures of ECT studies presented here
were obtained after injection ofFab from MAb 35. Our selection
of the Fab fragments is in agreement with Larson et al. (34),
who also used Fab of high affinity MAb for imaging of mela-
nomas. It should be noted, however, that in some experimental
models, F(ab')2 fragments and even intact antibodies have been
reported to give better tumor localization than Fab (35, 36). The
poor results with these Fab fragments may be explained by a
too low affinity of the antibody. A relatively low affinity becomes
a limiting factor when a fragment with a single binding site is
used. In our experience, the Fab fragments from MAb with an
affinity lower than 5 X 108 M-' perform less well than F(ab')2
(Buchegger et al., manuscript in preparation). In addition, large
amounts of antibody fragments labeled with "'In through the
bifunctional chelating agent diethylenetriamine-pentaacetic acid
may accumulate in the kidney (36), whereas kidney accumu-
lation of '3'1-labeled MAb fragments was much less important
in our experimental studies (16).
The choice ofthe isotope is controversial. Tc-99m, the most
convenient and widely used isotope in nuclear medicine, would
be ideal if it had a physical half-life slightly longer than 6 h. The
methodology to label antibodies with a sufficiently high specific
activity of this isotope has been developed and the in vivo lo-
calization ofTc-99m-labeled MAb anti-cardiac myosin in myo-
cardial infarction has been reported (37). According to most
experimental results, however, it takes at least 24 h to obtain a
good localization in solid tumors; thus, the 6-h half-life of
Tc-99m appears to be too short.
"'In has a favorable half-life of 2.7 d, and excellent exper-
imental results have been obtained with "'In-labeled intact anti-
tumor antibodies (36). When "'In-labeled antibodies have been
injected into patients, however, a very high nonspecific uptake
has always been observed in the reticuloendothelium, especially
in the liver (26, 38), even when the DTPA coupling was per-
formed under mild conditions (25, 39). Since high nonspecific
liver uptake may interfere with the detection of liver metastases,
we considered this label not to be optimal for the evaluation of
colon carcinoma patients by immunoscintigraphy.
'l'I has the advantage of a long half-life (8 d) and has been
used by Chatal et al. (31) to detect a liver metastasis of colon
carcinoma as late as 11 d after injection of 1.4 mCi of 13'I-
labeled MAb. The major disadvantages of '31I are the emission
of beta rays, which limits its use for purely diagnostic tests, as
well as the rather high energy (364 keV) ofthe principal gamma
ray, which is not convenient for ECT because gamma cameras
have a low efficiency for high energy photon emitters.
In our opinion, the best presently available isotope for an-
tibody labeling is 1231. Its energy of 159 keV is perfectly adapted
for use in ECT (20). Although its half-life of 13 h is a little too
short, it can represent an optimal tracer when it is coupled to
the small Fab fragments which penetrate more easily into the
tumor and are rapidly cleared from the circulation (16, 18).
The use of fragments of the anti-CEA MAb 35 along with
1231 has given very encouraging clinical results: almost all (23
out of 24) primary tumors or local recurrences of colorectal
carcinoma were detected with both types of fragments within
24 h, and metastatic disease was detected in various organs, such
as liver, bone, and lung. The overall percentage ofdetection was
82% for F(ab')2 and 89% for Fab fragments.
It is of clinical interest that in nine patients with normal or
borderline serum CEA values (<5 ,gg/liter), tumor deposits could
be detected by radiolabeled MAb fragments and ECT. Further-
more, in four patients the improved immunoscintigraphy pro-
cedure described here was able to detect tumor deposits which
were either not suspected clinically or not found by standard
diagnostic methods, such as ultrasound or CT scan. In two of
these cases, the liver metastases were confirmed by surgery, and
in one of them the detected metastasis weighing -8 g (patient
20) could be entirely resected.
One of the limitations of the '231-labeled MAb fragment
method is the uptake of iodine by the stomach and its rapid
elimination by the urinary tract. These regular nonspecific ac-
cumulations, however, may also be used as anatomical land-
marks, as previously suggested by Berche et al. (13), and thus
be helpful for the topographic characterization of hot spots. In-
terestingly, two of the small tumors reported here, weighing 3
and 4.5 g, were detected near a very radioactive organ, the first
one near the left kidney (Fig. 4) and the second one behind the
urinary bladder (Fig. 5). One of the greatest advantages ofECT
is that it allows a distinction between tumor uptake of radiola-
beled antibodies from physiological organ concentration and
circulating radioactivity, without the need to use computerized
subtraction techniques which are prone to artifacts (19).
Another, more important, limitation of antibody fragments
which has to be mentioned is that the percentage of the injected
dose which localizes in tumor remains relatively low (<1%).
Even in the experimental animal, where we reached tumor to
normal tissue ratios of 82 with Fab fragments from MAb 35,
the percentage of injected dose was four times lower than for
intact MAb 35 (16). Therefore, if one considers the injection of
radioactive antibodies for therapeutic purposes, we are not cer-
tain that Fab fragments are the best carrier, as proposed by Larson
et al. (33, 34). Intact antibodies with their longer biological half-
life may have a better chance to deliver the necessary dose of
radioactivity into the tumor, as suggested by Order et al. (40).
Intact antibodies, however, will give higher background radio-
activity in the reticuloendothelial system. Since the therapeutic
index is determined by the ratio of radiation delivered to the
tumor to that delivered to the sensitive normal organs (33), it
is possible that a fragment of intermediary size such as F(ab')2
will be the most appropriate carrier for antibody-guided radio-
therapy. We have recently injected 100 mCi of '"'I coupled to
10 mg of F(ab')2 from MAb 35 into the hepatic artery of four
patients with advanced liver metastases of colon carcinoma. The
treatment was well tolerated, that is, no bone marrow toxicity
was observed, but no evidence of significant regression of the
large hepatic metastases was obtained (41).
For diagnostic purposes, however, the use of Fab fragments
labeled with 123I and detected by ECT, as described here, appears
to offer the best potential for the detection of early tumor re-
currences, a necessary condition to improve curability and sur-
vival in patients with colon carcinoma.
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